keyword
MENU ▼
Read by QxMD icon Read
search

entresto

keyword
https://www.readbyqxmd.com/read/27804100/rhabdomyolysis-after-coadministration-of-atorvastatin-and-sacubitril-valsartan-entresto%C3%A2-in-a-63-year-old-woman
#1
Eve S Faber, Madhavi Gavini, Ronald Ramirez, Richard Sadovsky
A 63-year-old woman previously stable on a regimen of atorvastatin 40 mg daily, carvedilol 25 mg twice daily, digoxin 0.125 mg daily, furosemide 40 mg daily, spironolactone 25 mg daily, rivaroxaban 15 mg daily, and enalapril 20 mg twice daily for heart failure developed rhabdomyolysis 26 days after enalapril was stopped and sacubitril/valsartan (Entresto™) started. The patient received sacubitril/valsartan at 24/26 mg twice daily for heart failure; however, after 26 days she developed muscle and skin pain...
December 2016: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27697814/european-drug-market-entries-2015-with-new-mechanisms-of-action
#2
Titus W P van den Heuvel, Adam F Cohen, Robert Rissmann
In this article, we consider the new drugs approved for the European market in 2015. We present a summary of the new mechanisms of action introduced and highlight three new mechanisms of action with a potentially high future impact: PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition (mepolizumab (Nucala®)) for asthma.
October 2016: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/27668049/entresto-sacubitril-valsartan-first-in-class-angiotensin-receptor-neprilysin-inhibitor-fda-approved-for-heart-failure
#3
Loretta Fala
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27378659/angiotensin-receptor-neprilysin-inhibitor-arni-clinical-studies-on-a-new-class-of-drugs
#4
Mauro Gori, Maurizio Volterrani, Massimo Piepoli, Michele Senni
Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
June 23, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27377680/the-metalloprotease-neprilysin-degrades-and-inactivates-apelin-peptides
#5
Shaun M K McKinnie, Conrad Fischer, Kelvin M H Tran, Wang Wang, Fabricio Mosquera, Gavin Y Oudit, John C Vederas
The apelinergic system is a mammalian peptide hormone network with key physiological roles. Apelin isoforms and analogues are believed to be promising therapeutics for cardiovascular disease. Despite extensive studies on apelin-13 degradation patterns, only one protease, angiotensin-converting enzyme 2 (ACE2), had been implicated in its physiological regulation. Through use of a peptide-based fluorescent probe, we identified the metalloprotease neprilysin (NEP, a target for Entresto used in treatment of heart failure) as an enzyme that cleaves apelin isoforms...
August 17, 2016: Chembiochem: a European Journal of Chemical Biology
https://www.readbyqxmd.com/read/27284124/%C3%A2-sacubitril-valsartan-for-heart-failure
#6
(no author information available yet)
▼ Sacubitril valsartan (Entresto-Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.(1) It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.(1-3) Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.
June 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/26992459/neprilysin-inhibition-with-sacubitril-valsartan-in-the-treatment-of-heart-failure-mortality-bang-for-your-buck
#7
REVIEW
A J Ansara, D M Kolanczyk, J M Koehler
WHAT IS KNOWN AND OBJECTIVE: Heart failure remains a leading cause of morbidity and mortality worldwide. Advanced therapies have prolonged survival in patients with advanced heart failure, but pharmacotherapeutic optimization remains the mainstay of treatment. It has been over 10 years since the last mortality-reducing medication has been approved by the Food and Drug Administration. This article reviews the background, current knowledge and data supporting the use of sacubitril/valsartan (Entresto(®) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure...
April 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/26976916/combined-angiotensin-receptor-antagonism-and-neprilysin-inhibition
#8
REVIEW
Scott A Hubers, Nancy J Brown
Heart failure affects ≈5.7 million people in the United States alone. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone antagonists have improved mortality in patients with heart failure and reduced ejection fraction, but mortality remains high. In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex...
March 15, 2016: Circulation
https://www.readbyqxmd.com/read/26975167/-angiotensin-receptor-and-neprilysin-inhibition-a-new-option-against-heart-failure
#9
REVIEW
Claudia Bruhn
The molecular combination of sacubitril and valsartan (Entresto) is a new drug for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, instead of an ACE inhibitor or an angiotensin-receptor blocker (ARB). In studies, sacubitril/ valsartan was superior to enalapril in reducing the risks of death and hospitalization for heart failure...
January 2016: Medizinische Monatsschrift Für Pharmazeuten
https://www.readbyqxmd.com/read/26873495/sacubitril-valsartan-a-review-in-chronic-heart-failure-with-reduced-ejection-fraction
#10
Paul L McCormack
Sacubitril/valsartan (Entresto™; LCZ696) is an orally administered supramolecular sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan, which was recently approved in the US and the EU for the treatment of chronic heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). In the large, randomized, double-blind, PARADIGM-HF trial, sacubitril/valsartan reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure (composite primary endpoint) significantly more than the angiotensin converting enzyme (ACE) inhibitor enalapril...
March 2016: Drugs
https://www.readbyqxmd.com/read/26864319/different-susceptibility-of-b-type-natriuretic-peptide-bnp-and-bnp-precursor-probnp-to-cleavage-by-neprilysin-the-n-terminal-part-does-matter
#11
Alexander G Semenov, Alexey G Katrukha
BACKGROUND: Protease neprilysin is known to be responsible for the degradation of natriuretic peptides. A recent heart failure (HF) drug, LCZ696 (Entresto(TM)), that combines a neprilysin inhibitor and an angiotensin II receptor inhibitor was suggested to augment circulating B-type natriuretic peptide (BNP) concentrations, making the results of BNP measurements diagnostically ambiguous. Because the main form of measured BNP in HF patients is represented by its uncleaved precursor, proBNP, it is important to know the susceptibility of proBNP to cleavage by neprilysin...
April 2016: Clinical Chemistry
https://www.readbyqxmd.com/read/26689034/sacubitril-valsartan-entresto-the-next-blockbuster-medication
#12
Chance D Wachholtz, William J Hayes
No abstract text is available yet for this article.
November 2015: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/26642078/sacubitril-valsartan-lcz696-for-the-treatment-of-heart-failure
#13
REVIEW
Mauro Gori, Michele Senni
The PARADIGM-HF study, a large outcome trial in heart failure and reduced ejection fraction (HFrEF), has recently shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), still commonly referred to as LCZ696, compared to ACE-inhibitor therapy, possibly leading us to a new era for heart failure (HF) treatment. LCZ696 represents a first-in-class drug acting through inhibition of angiotensin receptor and neprilysin, thus modulating the renin angiotensin aldosterone system and vasoactive substances such as natriuretic peptides...
2016: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/26557227/entresto-sacubitril-valsartan-first-in-class-angiotensin-receptor-neprilysin-inhibitor-fda-approved-for-patients-with-heart-failure
#14
Loretta Fala
No abstract text is available yet for this article.
September 2015: American Health & Drug Benefits
https://www.readbyqxmd.com/read/26466333/sacubitril-valsartan-a-novel-cardiovascular-combination-agent
#15
REVIEW
Alexandra M Sible, James J Nawarskas, David Alajajian, Joe R Anderson
Sacubitril/valsartan [LCZ696 (Entresto), Novartis Pharmaceuticals Corp.] is the first in a new class of drugs that combines neprilysin inhibition with angiotensin II receptor antagonism, the combination of which acts to increase endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system. Sacubitril/valsartan has been studied in the treatment of hypertension, heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF) and has demonstrated clinical efficacy in blood pressure reduction in hypertensive patients with and without HFpEF and a reduction in hospitalizations and mortality for patients with HFrEF...
January 2016: Cardiology in Review
https://www.readbyqxmd.com/read/26284725/sacubitril-valsartan-entresto-for-heart-failure
#16
(no author information available yet)
No abstract text is available yet for this article.
August 18, 2015: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/26218791/sacubitril-valsartan-entresto-for-heart-failure
#17
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 3, 2015: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"